Conquering Diseases

Open-Label Study To Evaluate The Safety And Efficacy Of Caba-201 In Subjects With A Type Of Lupus

Description

Seeking men and women with Active Systemic Lupus Erythematosus (SLE) to undergo testing of CABA-201, an Autologous CD19-specific Chimeric Antigen Receptor T cells,

Overview

We are studying the effects of CABA-201 in individuals with active SLE to better understand how well this works (efficacy) and how safe and tolerable this treatment is.

What we're hoping for

To determine if treatment with CABA-201 is effective in participants with active SLE, as well as how well this works and how safe it is for these individuals.

Additional Information

ClinicalTrials.gov Identifier: NCT06121297

 Principal Investigator

Roberto  Caricchio, MD

UMass Chan Medical School

 Study Contact

The Cancer  Research Office

508-856-3216

Cancer.research@umassmed.edu

 Location

UMass Chan University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989